1、Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M, Fang H, Mi J, Yang X, Xiao H, Mark Minden, Du Y, Chen Z, and Zhang J.#. PML/RAR? Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia.. cancer cell,2010;17, 186-197
2、Wang K, Fang H, Xiao D, Zhu X, He M, Pan X, Shi J, Zhang H, Jia X, Du Y and Zhang J. Converting Redox Signaling to Apoptotic Activities by Stress-Responsive Regulators HSF1 and NRF2 in Fenretinide Treated Cancer Cells.. PLoS One,2009;4, e7538
3、 Fang H, Wang KK and Zhang J. Transcriptome and proteome analysis of drug interaction with natural products. . Current Drug Metabolism,2008;9:1038-1048
4、Fu SJ, Zhao HG, Abzhanov A, Crawford K, Zhou O-M L, Du YZ, Kuo WP, Zhang J, Jiang M and Jin G.. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses.. BMC Genomics,2008;1:9:369
5、Rodius S, Moes M, Chaloin O, Schffner-Reckinger E, Lippens G, Zhang J and Kieffer N. . The talin rod IBS2 α -helix interacts with the β3 integrin cytoplasmic tail membrane proximal helix by establishing charge complementary salt bridges.. JBC,2008;3(35):24212-23
6、Zhou GB, Zhang J#, Chen SJ and Chen Z.. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil. Trans. R. Soc. B.,2007;362:959-971
|
